Atlas Trials

A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)

Clinical trial NCT03369236 · COMPLETED

Trial details

NCT number
NCT03369236
Sponsor
Alexion Pharmaceuticals, Inc.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
C3 GlomerulopathyC3 GlomerulonephritisDense Deposit Disease
Start date
2018-06-12
Primary completion
2019-12-11
Enrollment
13

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.